The stock of Kintara Therapeutics Inc (KTRA) has seen a -11.55% decrease in the past week, with a -8.46% drop in the past month, and a 107.29% flourish in the past quarter. The volatility ratio for the week is 7.75%, and the volatility levels for the past 30 days are at 17.94% for KTRA. The simple moving average for the past 20 days is -9.75% for KTRA’s stock, with a -54.77% simple moving average for the past 200 days.
Is It Worth Investing in Kintara Therapeutics Inc (NASDAQ: KTRA) Right Now?
Additionally, the 36-month beta value for KTRA is 0.93. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for KTRA is 55.30M and currently, short sellers hold a 5.15% ratio of that float. The average trading volume of KTRA on July 22, 2024 was 12.76M shares.
KTRA) stock’s latest price update
Kintara Therapeutics Inc (NASDAQ: KTRA) has experienced a decline in its stock price by -0.18 compared to its previous closing price of 0.25. However, the company has seen a fall of -11.55% in its stock price over the last five trading days. prnewswire.com reported 2024-07-08 that KVA12123 is a rationally targeted, anti-VISTA antibody checkpoint inhibitor to reverse VISTA immune suppression and remodel the tumor microenvironment (TME) to overcome acquired resistance to immunotherapies KVA12123 is currently in a Phase 1/Phase 2 clinical study as a monotherapy and in combination with Merck’s anti-PD1 therapy, KEYTRUDA® (pembrolizumab), in patients with advanced solid tumors To date, KVA12123 has demonstrated a favorable clinical safety and tolerability profile observed with no dose limiting toxicities and no evidence of Cytokine Release Syndrome (CRS) associated toxicities at doses examined Concurrent $5 million investment from existing TuHURA shareholder preserves TuHURA’s strong balance sheet for advancing its IFx-2.0 Phase 3 accelerated approval trial and novel bi-functional ADCs TAMPA, Fla. and SAN DIEGO, July 8, 2024 /PRNewswire/ — TuHURA Biosciences, Inc. (“TuHURA”), a Phase 3 registration-stage immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, and Kintara Therapeutics, Inc. (Nasdaq: KTRA) (“Kintara”), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced TuHURA has entered into an Exclusivity and Right of First Offer Agreement (the “Agreement”) with Kineta, Inc. (Nasdaq: KA) (“Kineta”) for the potential acquisition of Kineta’s KVA12123 anti-VISTA antibody and related rights and assets associated with and derived from the asset.
KTRA Trading at 9.37% from the 50-Day Moving Average
After a stumble in the market that brought KTRA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -94.97% of loss for the given period.
Volatility was left at 17.94%, however, over the last 30 days, the volatility rate increased by 7.75%, as shares surge +0.81% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +67.63% upper at present.
During the last 5 trading sessions, KTRA fell by -12.44%, which changed the moving average for the period of 200-days by -93.56% in comparison to the 20-day moving average, which settled at $0.2789. In addition, Kintara Therapeutics Inc saw 48.38% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for KTRA
The total capital return value is set at -1.57. Equity return is now at value -192.23, with -131.55 for asset returns.
Currently, EBITDA for the company is -14.75 million with net debt to EBITDA at 0.68. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.04.
Conclusion
In conclusion, Kintara Therapeutics Inc (KTRA) has seen mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
